Validation of Dose Estimation Methods and Measurement of Normal Liver Dose in Y-90 Therasphere Therapy with Quantitative Nuclear Imaging
This research is being conducted to determine the best way to estimate tumor and liver treatment doses in patients with hepatocellular carcinoma (HCC) treated with TheraSphere. The study focuses on the comparison of imaging before and after the TheraSphere procedure, rather than the procedure itself.
Patients with HCC recommended for radioembolization.
Patients with HCC recommended for radioembolization receive TheraSphere therapy, and immediately after, a PET/CT scan (positron emission tomography combined with a CT scan) and SPECT (single photon emission computer tomography) of the liver are performed. The two images are compared to measure the dose that was absorbed by the tumor(s) and the dose absorbed by the non-tumor areas of the liver. Participants will be on study for 1 day consisting of the 24 hours after the procedure and then followed for 30 days.
10/01/2014 04:03 AM